Aquestive therapeutics announces pivotal study for anaphylm™ (epinephrine) sublingual film successfully meets primary and secondary endpoints and provides clinical development update following fda meeting

Warren, n.j., march 14, 2024 (globe newswire) -- aquestive therapeutics, inc. (nasdaq: aqst), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today released positive topline clinical data from its phase 3 pivotal pharmacokinetic (pk) clinical study of anaphylm™ (epinephrine) sublingual film and findings from the fda type c meeting. anaphylm is the company's first and only orally administered epinephrine prodrug product candidate under development for the treatment of severe life-threatening allergic reactions, including anaphylaxis.
AQST Ratings Summary
AQST Quant Ranking